Please select the market sector you are interested in.
Please select the university you are interested in.
Narrow your search with a few keywords.
Register now to receive technology alerts for your preferred market sector(s).
University: University of St Andrews
Sector(s): Life Sciences
About Opportunity:
There is increasing resistance to currently available influenza antivirals (Relenza, Tamiflu).
Our approach targets the host rather than the virus, overcoming the drug resistance that is a major problem with the fast evolving influenza virus. Our approach has advantages over removing sialic acid receptors with sialidase, as this approach can unmask cryptic receptors for other respiratory pathogens. We have developed multivalent proteins based on the sialic acid binding domain of Vibrio cholerae sialidase that have varying binding affinities from micromolar to nanomolar (see http://www.jbc.org/content/284/11/7339). These proteins recognize terminal sialic acids, independent of linkage (α(2,3), α(2,6), and α(2,8)), and hence bind to receptors in the respiratory tract that are recognized by avian or human viruses. As a result, the virus is prevented from attaching to its receptor in the initial stages of infection.
Key Benefits:
Applications:
IP Status:
The University of St. Andrews has applied for patent protection and this entered the PCT phasein September 2009.The University would welcome enquiries from parties interested in entering into commercialdiscussions in regard to developing the recombinant proteins as antiviral treatments.Further information/discussions would be held under a Confidentiality Agreement.
Please enter your name.
Please enter the name of the company you work for.
Please select the country you are in.
Please enter your email address.
Please enter your telephone number.
To help us process your enquiry faster please enter some details about the information you are interested in.
Please prove you are a human by completing this simple image recognition task.